CSL BEHRING LLC for CSL BEHRING LLC
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 6218, S. 3587--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 2905--Medicare Intravenous Immune Globulin Enhancement Act--Legislation that would create a demonstration home infusion benefit under Medicare Part B for intravenous immune globulin when used in the treatment of chronic inflammatory dymyelinating polyneuropathy. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. Raising awareness regarding COVID-19 and the potential for convalescent plasma to be used in the creation of a hyper-immune globulin therapy. S. 3129--Lower Costs, More Cures Act of 2019--Drug Pricing provisions included in presidential executive orders versus the policies put forward in legislation such as S. 3129 Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
| JULIA GRANT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.